Key result
Patients with type 2 diabetes mellitus had significantly higher circulating betatrophin levels compared to normal controls (4.79±1.53 vs. 2.79±1.11 ng/mL; p=0.001).
Population
75 subjects in Iran, comprising 40 patients with type 2 diabetes mellitus and 35 age-, sex-, and BMI-matched…
Design
Case-control
Authors
Loading...
Elevated betatrophin may mark atherogenic risk in T2DM; hypothesis-generating and requires prospective validation before clinical adoption.
Case-Control (n=75)
Absolute Event Rate: 4.79% vs 2.79%
p-value: p=0.001
Circulating betatrophin levels are significantly elevated in patients with T2DM and positively correlate with atherogenic lipid profiles.
Ghasemi et al. (2015) conducted a case-control in Type 2 diabetes mellitus (n=75). Type 2 diabetes mellitus vs. Normal control subjects was evaluated on Circulating betatrophin levels (ng/mL) (p=0.001). Patients with type 2 diabetes mellitus had significantly higher circulating betatrophin levels compared to normal controls (4.79±1.53 vs. 2.79±1.11 ng/mL; p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: